The market attempted to extend the previous day's rally but selling pressure in late trade pulled it down to close marginally lower on October 9. However, the market breadth remained positive due to buying in the broader space, with about 1,708 shares advancing against 802 declining shares on the NSE. Volatility is expected to continue in the market, with support at the current week's low. Below a...

Brokerage firm Investec has kept a bullish stance on drugmaker Cipla, banked on expectations of mid-teens growth in the India pharma market, and easing regulatory challenges at its Goa plant.The brokerage remains optimistic of Cipla achieving 12-13 percent on-year growth in sales within the Indian pharma market. Alongside that, Investec also sees a classification from the US Food and Drug Administ...

Cipla Ltd shares have been making higher highs and higher lows, indicating bullish signals across all major time frames. The pharma sector has been in the limelight for the past few sessions, with Nifty Pharma reaching a 52-week high at 19,771.According to Arun Kumar Mantri, Founder of Mantri Finmart, "The stock-specific volumes have been encouraging in the latest bullish move, followed by good pr...

Shares of Cipla soared 4 percent in opening trade on May 15, after three block deals in the counter took place on the exchanges. Around 2.04 crore shares, making up a 2.52 percent stake in drugmaker Cipla changed hands in the three block deals.The company later confirmed that its promoters, the Hamied family sold a 2.5 percent stake in the drugmaker.CNBC-Awaaz had also reported on May 14 that the ...

The strongest argument for defense stocks at this point is their bulging order books. Of course, the market is ignoring execution risks right now because the quarterly earnings growth so far has not given any cause for worry. But there is another risk that the market may be overlooking, according to a senior portfolio manager Short Call spoke to.If defense companies continue to make super profits,...